Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 1, 2016, Pages 4.e11-4.e17

  Hahn, Noah M ^a,b   Knudsen, Beatrice S ^c   Daneshmand, Siamak ^d,e   Koch, Michael O ^a   Bihrle, Richard ^a   Foster, Richard S ^a   Gardner, Thomas A ^a   Cheng, Liang ^a   Liu, Ziyue ^a   Breen, Timothy ^a   Fleming, Mark T ^f   Lance, Raymond ^f   Corless, Christopher L ^d   Alva, Ajjai S ^g,h   Shen, Steven S ⁱ   Huang, Fangjin ^c   Gertych, Arkadiusz ^c   Gallick, Gary E ^j   Mallick, Jayati ^c   Ryan, Christopher ^d   Galsky, Matthew D ^k   Lerner, Seth P ^g   Posadas, Edwin M ^c   Sonpavde, Guru ^l   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

ⁱ HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

Bladder; Dasatinib; Neoadjuvant therapy; Protein kinase inhibitors; Src family kinases; Translational medical research; Urothelial carcinoma

Indexed keywords

CASPASE 3; DASATINIB; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CONSTIPATION; CYSTECTOMY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEARTBURN; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE FISTULA; LUNG EMBOLISM; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DASATINIB; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84952638967     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.08.005     Document Type: Article

References (25)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015, 65:5-29.
2. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. N Engl J Med 2003, 349:859-866.
3. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party tEOfR, Treatment of Cancer Genito-Urinary Tract Cancer Group tABCSG, The National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Group CUEdTO International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
4. Vale C.L. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-206.
5. Dash A., Galsky M.D., Vickers A.J., Serio A.M., Koppie T.M., Dalbagni G., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006, 107:506-513.
6. Miles B.J., Fairey A.S., Eliasziw M., Estey E.P., Venner P., Finch D., et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010, 4:263-267.
7. Reardon Z.D., Patel S.G., Zaid H.B., Stimson C.J., Resnick M.J., Keegan K.A., et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol 2015, 67:165-170.
8. David K.A., Milowsky M.I., Ritchey J., Carroll P.R., Nanus D.M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007, 178:451-454.
9. Boyer B., Bourgeois Y., Poupon M.F. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002, 21:2347-2356.
10. Levitt J.M., Yamashita H., Jian W., Lerner S.P., Sonpavde G. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther 2010, 9:1128-1135.
11. Thomas S., Overdevest J.B., Nitz M.D., Williams P.D., Owens C.R., Sanchez-Carbayo M., et al. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res 2011, 71:832-841.
12. Wu Y., Moissoglu K., Wang H., Wang X., Frierson H.F., Schwartz M.A., et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A 2009, 106:5807-5812.
13. Qayyum T., Fyffe G., Duncan M., McArdle P.A., Hilmy M., Orange C., et al. The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br J Cancer 2012, 106:1187-1195.
14. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
15. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007, 29:2289-2308.
16. Sonpavde G., Goldman B.H., Speights V.O., Lerner S.P., Wood D.P., Vogelzang N.J., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009, 115:4104-4109.
17. Dhar N.B., Klein E.A., Reuther A.M., Thalmann G.N., Madersbacher S., Studer U.E. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 2008, 179:873-878. [discussion 8].
18. Gray P.J., Lin C.C., Jemal A., Shipley W.U., Fedewa S.A., Kibel A.S., et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 2014, 88:1048-1056.
19. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
20. Saini S., Arora S., Majid S., Shahryari V., Chen Y., Deng G., et al. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) 2011, 4:1698-1709.
21. Margulis V., Lotan Y., Karakiewicz P.I., Fradet Y., Ashfaq R., Capitanio U., et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009, 101:114-119.
22. Karam J.A., Lotan Y., Karakiewicz P.I., Ashfaq R., Sagalowsky A.I., Roehrborn C.G., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007, 8:128-136.
23. Iravani S., Mao W., Fu L., Karl R., Yeatman T., Jove R., et al. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest 1998, 78:365-371.
24. Fanning P., Bulovas K., Saini K.S., Libertino J.A., Joyce A.D., Summerhayes I.C. Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res 1992, 52:1457-1462.
25. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.